

<u>CSF biomarker</u>	<u>Research Group</u>	<u>n number of PSP patients</u>	<u>Median/mean biomarker concentration in PSP patients</u>	<u>Median biomarker concentration in healthy controls</u>	<u>Statistical significance of difference in biomarker concentration between PSP patients and controls</u>
t-tau	Sismuth et al (16)	27	204ng/L	171ng/L	No significance
	Hall et al (17)	45	429ng/ml	473ng/ml	No significance
p-tau	Sismuth et al (16)	27	31.7ng/L	Not determined	Not determined
	Hall et al (17)	45	43ng/ml	49ng/ml	P < 0.001
33/55kDa tau form ratio	Borroni et al (19)	21	0.504 ratio	0.899 ratio	P < 0.0001
	Kuiperij et al (20)	Not applicable	Not detected	Not detected	Not determined
4R-tau isoform	Luk et al (21)	44	12pg/ml	37pg/ml	P < 0.01
N-terminal tau (Tau12 capture antibody)	Wagshal et al (24)	24	321.5pg/ml	409.9pg/ml	P < 0.05
Mid-domain tau (HT7 capture antibody)	Wagshal et al (24)	24	546.2pg/ml	639.7pg/ml	P < 0.05
NF-L	Hall et al (17)	45	3190ng/ml	860ng/ml	P < 0.001
	Magdalinou et al (31)	33	2219ng/L	560ng/L	P < 0.0001
NF-H	Brettschneider et al (28)	21	2.9ng/ml	0.15ng/ml	P < 0.05
GFAP	Sismuth et al (16)	27	9.5ng/L	8ng/L	No significance
YKL-40	Magdalinou et al (31)	33	21.5ng/L×10 ⁴	12.4ng/L×10 ⁴	P < 0.0001
sAPP α	Magdalinou et al (31)	33	440ng/ml	576ng/ml	P < 0.0007
sAPP β	Magdalinou et al (31)	33	256ng/ml	336ng/ml	P < 0.009

Supplementary table: CSF biomarkers used in the diagnosis of PSP